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Metoprolol is used for phenotyping of cytochrome P450 (CYP) 2D6, a CYP isoform
considered not to be inducible by inducers of the CYP2C, CYP2B, and CYP3A
families such as rifampicin. While assessing CYP2D6 activity under basal conditions
and after pre-treatment with rifampicin in vivo, we surprisingly observed a drop in the
metoprolol/α-OH-metoprolol clearance ratio, suggesting CYP2D6 induction. To study
this problem, we performed in vitro investigations using HepaRG cells and primary
human hepatocytes (before and after treatment with 20 µM rifampicin), human liver
microsomes, and CYP3A4-overexpressing supersomes. While mRNA expression levels
of CYP3A4 showed a 15- to 30-fold increase in both cell models, mRNA of CYP2D6
was not affected by rifampicin. 1′-OH-midazolam formation (reflecting CYP3A4 activity)
increased by a factor of 5–8 in both cell models, while the formation of α-OH-metoprolol
increased by a factor of 6 in HepaRG cells and of 1.4 in primary human hepatocytes.
Inhibition studies using human liver microsomes showed that CYP3A4, 2B6, and 2C9
together contributed 19.0 ± 2.6% (mean ± 95%CI) to O-demethylation, 4.0 ± 0.7%
to α-hydroxylation, and 7.6 ± 1.7% to N-dealkylation of metoprolol. In supersomes
overexpressing CYP3A4, metoprolol was α-hydroxylated in a reaction inhibited by
the CYP3A4-specific inhibitor ketoconazole, but not by the CYP2D6-specific inhibitor
quinidine. We conclude that metoprolol is not exclusively metabolized by CYP2D6.
CYP3A4, 2B6, and 2C9, which are inducible by rifampicin, contribute to α-hydroxylation,
O-demethylation, and N-dealkylation of metoprolol. This contribution is larger after CYP
induction by rifampicin but is too small to compromise the usability of metoprolol
α-hydroxylation for CYP2D6 phenotyping.
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INTRODUCTION
Metoprolol is a cardioselective beta-blocker that is used mainly in the treatment of arterial
hypertension (Hansson et al., 1999), heart failure (MERIT-HF Study Group, 1999), and
myocardial infarction (Chen et al., 2005). Intestinal absorption of metoprolol is rapid and almost
complete; however, due to an extensive first pass metabolism (Regardh and Johnsson, 1980),
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the bioavailability of metoprolol is only approximately 50%.
The half-life is in the range of 3–4 h in young adults
and between 7–9 h in elderly patients (Rigby et al., 1985).
Metoprolol is heavily biotransformed with less than 5% of
an oral dose being excreted in non-metabolized form by the
kidneys (Regardh and Johnsson, 1980; McGourty et al., 1985;
Rigby et al., 1985; Johansson et al., 2007). Approximately
70% of orally administered metoprolol is metabolized by
CYP2D6 (Johnson and Burlew, 1996). Major oxidative pathways
are O-demethylation to O-demethylmetoprolol and its further
oxidation to the corresponding metoprolol phenylacetate (65%
of the oral dose recovered in urine); N-dealkylation to
N-deisopropylmetoprolol (10%), which may be transaminated
and the resulting aldehyde oxidized to the corresponding acid;
and α-hydroxylation to α-OH-metoprolol (10%) (Borg et al.,
1975) (Figure 1A).
Whereas the carboxylic acid metabolites have no
pharmacological activity, the α-OH-metabolite and
O-demethylmetoprolol are active, but only contribute
approximately 10% of the total beta-blocking activity of
metoprolol (Regardh et al., 1974). Importantly, in contrast to the
formation of the carboxylic acid metabolites, the α-hydroxylation
of metoprolol only involves one enzymatic step, which is
considered to be mediated exclusively by CYP2D6 (McGourty
et al., 1985; Otton et al., 1988). Furthermore, the metabolism of
metoprolol is stereoselective; in extensive CYP2D6 metabolizers
(CYP2D6 EM), R-metoprolol has a 40% higher clearance than
S-metoprolol (Blake et al., 2013).
Due to the exclusive nature by which CYP2D6 is responsible
for α-hydroxylation of metoprolol, this step in the metabolic
pathway of metoprolol has previously been used for the
assessment of CYP2D6 activity in vivo (Tamminga et al.,
2001; Sharma et al., 2004; Frank et al., 2007; Donzelli et al.,
2014; Derungs et al., 2016) and in vitro (Birkett et al.,
1993). We have recently published a clinical study in healthy
volunteers investigating the effect of CYP inhibitors and inducers
on the Basel phenotyping cocktail, which contains six low-
dosed commercially available drugs (caffeine, efavirenz, losartan,
omeprazole, metoprolol, and midazolam) (Derungs et al., 2016).
After CYP induction with rifampicin, we not only observed
a change in the phenotyping metric for CYP1A2, CYP2B6,
CYP2C9, CYP2C19, and CYP3A4, but, albeit small, also for
CYP2D6. CYP2D6 activity was evaluated through use of the
metabolic ratio of metoprolol and its α-OH-metabolite, as well
FIGURE 1 | Metabolic pathways of metoprolol and influence of CYP induction on the clearance of metoprolol and midazolam in vivo. (A) α-Hydroxylation (I),
O-demethylation (II), and N-dealkylation (III) represent the 3 principle pathways of metoprolol metabolism, (B) midazolam clearance before and after treatment with
rifampicin (600 mg rifampicin per day for 7 days), (C) metoprolol clearance before and after treatment with rifampicin (600 mg rifampicin per day for 7 days), and (D)
α-OH-metoprolol exposure before and after treatment with rifampicin (600 mg rifampicin per day for 7 days). MDZ: midazolam, MTP: metoprolol.
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as the corresponding AUC0−24 h ratio. As CYP2D6 is considered
to be non-inducible (Eichelbaum et al., 1986; Rae et al., 2001;
Madan et al., 2003; Wenk et al., 2004; Glaeser et al., 2005;
Gerets et al., 2012), this result was surprising and difficult to
interpret.
Since it has been shown in a clinical study that the metabolism
of metoprolol cannot be completely inhibited by quinidine
(Johnson and Burlew, 1996), an efficient and specific CYP2D6
inhibitor (Hutzler et al., 2003; Ai et al., 2009), it is likely
that apart from CYP2D6, other CYP isoforms are involved in
the oxidative degradation of metoprolol, possibly also in its
α-hydroxylation. Taking into account the results of our in vivo
study (Derungs et al., 2016), we predicted that these additional
CYPs had to be inducible by rifampicin. In order to solve
these questions, we decided to investigate metoprolol metabolism
in vitro using two different hepatocyte systems as well as human
liver microsomes and supersomes. The data obtained by our
in vitro investigations confirmed that CYPs other than CYP2D6
are involved in metoprolol metabolism, explaining the decrease
in the metoprolol/α-OH-metoprolol ratio after treatment with
rifampicin observed in vivo.
MATERIALS AND METHODS
Chemicals and Reagents
Metoprolol, α-OH-metoprolol, O-demethylmetoprolol,
metoprolol phenylacetate, and metoprolol-d7 were purchased
from TRC (Toronto, Canada). 1′-OH-midazolam and
midazolam-d6 were acquired from Lipomed (Arlesheim,
Switzerland), while rifampicin, ketoconazole, quinidine, and
β-glucuronidase (type HP-2 from Helix pomatia) were obtained
from Sigma-Aldrich (Sigma-Aldrich Chemie GmbH, Buchs,
Switzerland). Midazolam was provided by Roche (Hoffmann-La
Roche, Basel, Switzerland). Formic acid, HPLC grade methanol,
and HPLC grade water were purchased from Merck (Darmstadt,
Germany). The media used were purchased from GIBCO
(Lucerne, Switzerland).
Stock solutions, calibration spiking solutions, and quality
controls were prepared in DMSO. Calibration standards and
quality controls were prepared by enriching the respective
medium with the corresponding spiking solutions. Internal
standard solutions containing the deuterated cocktail probe
drugs were prepared in methanol.
Human Liver Microsomes and Cell
Culture
Pooled human liver microsomes (HLM; Lot #38289), and
recombinant human CYP3A4 supersomes (rhCYP3A4 + P450
reductase + cytochrome b5, Lot #4070007), and NADPH
regenerating solutions A and B (A, containing NADP+, glucose-
6-phosphate, and MgCl2; B, containing glucose-6-phosphate
dehydrogenase) were purchased from Corning Life science
(Woburn, MA, United States). Microsomes and supersomes were
stored at−80◦C until used.
HepaRG cells were purchased from Biopredic International
(Rennes, France) as undifferentiated cryopreserved cells with the
associated medium. Freshly split HepaRG cells were seeded at
9000 cells/well in 96-well plates (or 0.05 × 106 cells/well in 24-
well plates) and treated over the course of the next 4 weeks as
previously described (Aninat et al., 2006).
Primary cryopreserved human hepatocytes (Life
Technologies, Lot #Hu8119 and Lot #Hu8124) were plated
at 0.05 × 106 cells/well in collagen type-1 precoated 96-well
plates (or 0.25 × 106 cells/well in 24-well plates) in William’s
E medium supplemented with 10% FCS (v/v), 1% L-glutamine
200 mM (v/v), 1% Pen Strep (v/v), 0.1% dexamethasone 100 µM
(v/v), and 0.1% insulin 100 µM (v/v), and then incubated at 37◦C
in the presence of 5% CO2 and 95% humid air.
In Vivo Assessment of CYP Induction
The in vivo characterization of the Basel phenotyping cocktail
has been described in detail in prior publications (Donzelli
et al., 2014; Derungs et al., 2016). The data presented here
origin from one of these studies published previously (Derungs
et al., 2016). The study had been approved by the local
ethics committee (Ethikkommission Basel) and the national
regulatory authorities (Swiss Agency for Therapeutic Products,
Swissmedic) and has been conducted in accordance with
the ethical standards of the Declaration of Helsinki. It was
a single-center, randomized, two-way crossover study1 (ID:
NCT01386593) that was conducted at the Phase I Research
Unit, University Hospital Basel, Switzerland. In this study, CYP
induction had been achieved by treating 15 healthy volunteers
with 600 mg rifampicin per day for 7 days. Subjects ingested
12.5 mg metoprolol and 2 mg midazolam (and other CYP
substrates) before and after CYP induction by rifampicin. Plasma
samples were obtained and analyzed as described previously
(Derungs et al., 2016). We determined the AUC using the
trapezoidal rule and apparent clearance (Cl/F) by dividing the
oral dose administered for both metoprolol and midazolam with
the respective AUCs. We used the ratio between the induced and
the basal state of the Cl/F of midazolam as a marker of CYP3A4
induction.
Quantification of Gene Expression
HepaRG cells and primary cryopreserved human hepatocytes
were seeded in 24-well plates and treated for 48 h with
rifampicin 20 µM. A total of 350 µL of RLT buffer
(Qiagen, Hombrechtikon, Switzerland) was used to lyse the
respective liver cell models, after which the lysate was
transferred to Qiashredder columns and centrifuged for 2 min
at 13,000 rpm. From the eluate, total RNA was extracted
and purified according to the manufacturer’s instructions
(Qiagen, RNeasy mini extraction kit). The concentration of
the extracted RNA was measured spectrophotometrically at
260 nm on a NanoDrop 2000 (Thermo Fisher Scientific, Wohlen,
Switzerland). cDNA was reverse transcribed from the isolated
RNA using the Qiagen omniscript system. For quantitative rt-
PCR, 10 ng cDNA was used. Forward and reverse primers
for all CYPs tested, and endogenous references, Hypoxanthine
phosphoribosyltransferase 1 (HPRT1) and GAPDH, were
1clinicaltrials.gov
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TABLE 1 | Gene-specific primers for rt-PCR.
Target
Gene
Organism Primer Sequence (5′ → 3′) Length
(bp)
CYP2D6 human Fw TGTGCCCATCACCCAGAT 18
Rev AAGGTGGAGACGGAGAAGC 19
CYP3A4 human Fw TACACAAAAGCACCGAGTGG 20
Rev TGCAGTTTCTGCTGGACATC 20
HPRT1 human Fw GGTCCTTTTCACCAGCAAGCT 21
Rev TGACACTGGCAAAACAATGCA 21
GAPDH human Fw AGCCACATCGCTCAGACAC 19
Rev GCCCAATACGACCAAATCC 19
purchased from Microsynth (Balgach, Switzerland; listed in
Table 1). rt-PCR was performed using SYBR green (Roche
Diagnostics, Rotkreuz, Switzerland) on an ABI PRISM 7700
sequence detector (PE Biosystems, Rotkreuz, Switzerland).
Quantification of mRNA expression levels was performed using
the comparative-threshold cycle method (Livak and Schmittgen,
2001).
Functional Assessment of CYP Induction
HepaRG cells and primary cryopreserved human hepatocytes
were cultured in a 5% CO2 and 95% air-humidified atmosphere
at 37◦C. Induction treatment (rifampicin 20 µM) lasted
for 48 h, with the medium being changed every 24 h.
After medium change at 24 h, rifampicin (20 µM) was
added again to the medium. Rifampicin stock solution was
prepared in DMSO and further diluted in the appropriate
culture medium, to achieve a final DMSO concentration of
0.1% (v/v). Experimental control culture wells were treated
with solvent [DMSO, 0.1% (v/v)] alone. Following treatment
with rifampicin, CYP activity was assessed by the addition
of fresh medium containing the probe drugs (metoprolol
25 µM or midazolam 5 µM). Probe drugs were dissolved and
serially diluted to the required concentrations with DMSO.
The final concentration of DMSO during the incubation
was 0.2% (v/v). At selected time points (0, 15, 30, 45,
60, 90, 105, and 120 min), the incubation was stopped by
the addition of a threefold volume of ice-cold methanol
containing the respective internal standards. The bottoms of
the wells were scraped using a pipette tip, after which the
contents were transferred to an autosampler vial. After vigorous
shaking (10 min) and centrifugation (3220 × g; 30 min;
10◦C), the supernatants were stored at −20◦C until analysis
by liquid chromatography-tandem mass spectrometry (LC-
MS/MS).
To determine the total amount of 1′-OH-midazolam formed,
the entire content of the autosampler vials was evaporated using
a minivap microplate evaporator (Porvair Sciences Ltd., King’s
Lynn, Norfolk, United Kingdom). The analytes were then re-
suspended in 45 µl of the respective culture medium, to which
5 µl (500 units) of β-glucuronidase was added. Following a 12-h
incubation at 37◦C, the reaction was terminated by the addition
of methanol, after which the samples were treated in the same
manner as above.
Metabolism of Metoprolol and
Midazolam by Human Liver Microsomes
and by rhCYP3A4 Supersomes
The reaction mixture (final volume of 500 µL) contained the
probe drugs (metoprolol 25 µM or midazolam 5 µM), incubation
buffer (0.1 M potassium phosphate buffered saline, pH 7.4),
human liver microsomes (175 pmol cytochrome P450/500 µL) or
rhCYP3A4 (10 pmol CYP3A4/500µL) and a NADPH-generating
system. For inhibition studies, the reaction mixture was pre-
incubated with the specific inhibitors (concentrations indicated
in the figures) for 10 min prior to the addition of test compounds
and NADPH. The suspensions were incubated at 37◦C in a
thermomixer (compact 5350, Eppendorf, Hamburg, Germany).
Following the incubation in the absence (control) or presence
of inhibitors, the reactions were terminated at selected time-
points by transferring 50 µL of the incubation mixture into a
matrix autosampler vial, to which a threefold volume of ice-
cold methanol (containing the internal standards) was added.
After vigorous shaking (10 min) and centrifugation (3220 × g;
30 min; 10◦C) the samples were stored at −20◦C until analysis
by LC-MS/MS. The formation rate (pmol/min/pmol P450) in the
absence and the presence of the inhibitors was calculated from the
linear parts of the concentration-time curves and expressed as an
absolute value or as a percentage relative to the control values.
Quantification of Probe Substrate
Metabolites
A previously developed LC-MS/MS method (Donzelli et al.,
2014) was used to quantify the phase I metabolites of
metoprolol and midazolam. Chromatographic separation was
performed on a Shimadzu HPLC system (Shimadzu AG,
Reinach, Switzerland), coupled to a triple quadrupole tandem
mass spectrometer (API4000 or API5500, AB/MDS Sciex,
Concord, Canada), operating in positive electrospray ionization
mode. The total run time was 2.9 min. Inter-assay accuracy
(determined as the % bias) ranged from −8.6 to 8.9 and
inter-assay precision (determined as the CV%) was lower than
8.3 for all analytes. The lower limit of quantification (LLOQ)
utilizing the API 4000 was 0.25 ng/mL for α-OH-metoprolol
and 1′-OH-midazolam, whereas on the API5500 the LLOQ
for α-OH-metoprolol, O-demethylmetoprolol, and metoprolol
phenylacetate (see Figure 1A for chemical structures) was
0.025 ng/mL.
Data Analysis
The CYP activities were determined as the respective metabolite
formation rates corresponding to the slope in the metabolite
concentration versus time graphs. Metabolite concentrations
were quantified using standard curves of pure compounds as
previously described (Donzelli et al., 2014).
For induction experiments, metabolite formation rates were
determined as described above, and the fold change versus the
basal conditions was calculated as the ratio of the metabolite
formation rate in wells exposed to an inducer versus formation
rates in control wells.
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Experiments were carried out 5 times unless stated otherwise.
Means were compared with the two-tailed Student’s t-test
using GraphPad Prism 6.0 (GraphPad Software, San Diego,
CA, United States). Data are presented as mean ± SD unless
stated otherwise. Induction levels above twofold with statistically
significant differences (p < 0.05) were considered relevant.
Areas under the curve (AUC), from times 0–24 h after dosing
(AUC0−24 h), were estimated with non-compartmental methods
using Phoenix WinNonlin software (Certara, Princeton, NJ,
United States).
RESULTS
In Vivo Clearance of Metoprolol Before
and After Treatment With Rifampicin
We performed a clinical study using 15 healthy volunteers, where
we investigated the effect of pre-treatment with rifampicin on the
Basel phenotyping cocktail, which contains caffeine, efavirenz,
losartan, omeprazole, metoprolol, and midazolam as probe drugs.
We have reported the changes in the metabolic ratios induced by
rifampicin of the six substrates included in a previous publication
(Derungs et al., 2016). As expected, we observed an increase in the
clearance of midazolam (Figure 1B) in all subjects tested, which
is a marker of CYP3A4 activity (Link et al., 2008). Surprisingly,
we also observed a 25% increase in the clearance of metoprolol in
subjects treated with rifampicin compared to the basal conditions
(Figure 1C). An increase by 9% (statistically not significant)
was also observed in the formation of α-OH-metoprolol after
treatment with rifampicin (Figure 1D).
The findings regarding metoprolol suggested either an
induction of CYP2D6 by rifampicin and/or metabolism of
metoprolol by CYPs other than 2D6, which are inducible
by rifampicin. To study the induction of the metabolism of
metoprolol by rifampicin in more detail, we performed in vitro
investigations in HepaRG cells and primary human hepatocytes
as well as in human liver microsomes and supersomes.
mRNA Expression of CYP2D6 and
CYP3A4, and Midazolam and Metoprolol
Metabolism Before and After Rifampicin
in HepaRG Cells
First, we reproduced the in vivo findings in HepaRG cells,
which contain inducible CYPs (Berger et al., 2016). As shown
in Figure 2, we investigated the effect of CYP induction by
rifampicin on mRNA expression and activity of CYP2D6 and
CYP3A4.
In HepaRG cells, mRNA of CYP3A4 (determined as a positive
control) increased approximately 30-fold after treatment with
rifampicin (20 µM for 48 h) compared to basal conditions
(Figure 3A). In contrast, mRNA of CYP2D6 was not induced by
pre-treatment with rifampicin.
In agreement with the mRNA data, pre-treatment with
rifampicin was associated with a significant increase in the
formation of 1′-OH-midazolam (Figure 2B), reflecting induction
of CYP3A4 by rifampicin. In contrast to the results obtained
for CYP2D6 mRNA, pre-treatment with rifampicin was also
associated with a significant increase in α-OH-metoprolol
formation (Figure 2C). This result suggested that CYPs other
than CYP2D6 contribute to α-hydroxylation of metoprolol and
that the contribution becomes larger after CYP induction.
mRNA Expression of CYP2D6 and
CYP3A4, and Midazolam and Metoprolol
Metabolism Before and After Rifampicin
in 2D Primary Hepatocytes
In order to confirm the results obtained in HepaRG cells, we
performed similar experiments in primary human hepatocytes
(Lot #Hu8119). Identical to our findings in HepaRG cells, pre-
treatment with rifampicin was associated with a 16-fold increase
in CYP3A4 mRNA expression, whereas no increase in mRNA
expression levels could be observed for CYP2D6 (Figure 3A).
Pre-treatment with rifampicin led to a fivefold increase in
production of 1′-OH-midazolam (Figure 3B). Similar to the
findings in HepaRG cells, rifampicin increased α-hydroxylation
of metoprolol also in primary human hepatocytes (Figure 3C),
but to a lesser extent than in HepaRG cells. These findings
confirmed the results obtained with HepaRG cells and excluded
at the same time an artifact due to modified regulation of CYP
expression in the HepaRG hepatoma cell line.
Using a different batch of primary cryopreserved
human hepatocytes (Lot #Hu8124) we could confirm the
results regarding the formation of 1′-OH-midazolam and
α-hydroxylation of metoprolol (Figure 3D). Furthermore, we
also investigated the formation of O-demethyl-metoprolol
and its oxidation to metoprolol phenylacetate. Similar to
the increase in the formation of α-OH-metoprolol, pre-
treatment with rifampicin was also associated with an increase in
O-demethylation of metoprolol (factor 1.4) and in the conversion
of O-demethyl-metoprolol to the corresponding phenylacetate
metabolite (factor 1.6).
These experiments not only confirmed the previous results in
HepaRG cells and primary human hepatocytes, but also showed
that CYPs other than CYP2D6 contribute to O-demethylation of
metoprolol, the most important metabolic pathway of this drug
(Borg et al., 1975; Regardh and Johnsson, 1980).
CYPs Involved in the Metabolism of
Metoprolol in Human Liver Microsomes
Next, we investigated the metabolic pathways of metoprolol in
human liver microsomes in the presence of different inhibitors.
In the presence of quinidine, a specific and strong inhibitor of
CYP2D6 (Hutzler et al., 2003; Ai et al., 2009), α-hydroxylation,
O-demethylation, and N-dealkylation of metoprolol was not
blocked completely (Figures 4A–C and Table 2), again suggesting
the involvement of CYPs other than CYP2D6 in metoprolol
metabolism. In comparison, the formation of the phenylacetate
metabolite from O-demethylated metoprolol had a very low
activity and was blocked completely by quinidine (Figure 4D).
These findings were in agreement with the in vitro study of Otton
et al. (1988) and the in vivo studies of Lennard et al. (1982)
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FIGURE 2 | Effect of rifampicin on mRNA expression and metabolism of midazolam and metoprolol in HepaRG cells. HepaRG cells were exposed to 20 µM
rifampicin for 48 h. (A) mRNA expression of CYP2D6 and CYP3A4 before and after treatment with rifampicin, (B) formation of 1′-OH-midazolam before and after
treatment with rifampicin, and (C) formation of α-OH-metoprolol before and after treatment with rifampicin. Data are presented as mean ± SD. MDZ: midazolam,
MTP: metoprolol.
and of McGourty et al. (1985), showing residual metabolism of
metoprolol in the absence of functional CYP2D6.
Next, we investigated, which additional CYPs are involved in
the metabolism of metoprolol. In the presence of ketoconazole,
at the concentration used (1 µM) a specific inhibitor of CYP3A4
(Berger et al., 2016), all major metabolic pathways assessed
(O-demethylation, α-hydroxylation, and N-dealkylation) were
inhibited significantly by 9.9–17.5% (Table 2 and Supplementary
Figure 1). In comparison, the CYP2B6 inhibitor ticlopidine
significantly reduced the activities of all metabolic pathways
of metoprolol investigated by 20.2–24.8% (Table 2 and
Supplementary Figure 2). Similarly, the CYP2C9 inhibitor
sulfaphenazole reduced the activities of all metabolic pathways by
15.2–27.0%, reaching statistical significance for O-demethylation
and α-hydroxylation (Table 2, Supplementary Figure 3). In
contrast, the CYP2C19 inhibitor (+)-N-3-benzylnirvanol did
not significantly decrease the activity of metoprolol metabolism
(Table 2, Supplementary Figure 4).
These results indicated that the major part of metoprolol
is metabolized by CYP2D6, but that CYP3A4, CYP2B6
and CYP2C9 contribute significantly to the metabolism of
metoprolol. Since CYP3A4, 2B6, and 2C9 are inducible by
rifampicin (Berger et al., 2016), the results obtained in
microsomes supported our in vivo findings as well as the results
obtained in HepaRG cells and in primary human hepatocytes.
α-Hydroxylation of Metoprolol by
rhCYP3A4 Supersomes
In order to demonstrate directly that CYP3A4 can α-hydroxylate
metoprolol, we performed experiments using recombinant
supersomes expressing CYP3A4 (rhCYP3A4). To ensure
that these supersomes do not contain CYP2D6 activity, we
exposed them to dextromethorphan, a typical CYP2D6 substrate
(Frank et al., 2007). The conversion to dextrorphan was not
quantifiable, excluding a significant CYP2D6 activity (data not
shown).
As shown in Figure 5A, the formation of 1′-OH-midazolam
from midazolam by CYP3A4 overexpressing supersomes was
rapid, showing non-linearity after 4 min of incubation due to
substrate depletion. Midazolam 1′-hydroxylation could almost
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FIGURE 3 | Effect of rifampicin on mRNA expression and metabolism of midazolam and metoprolol in primary human hepatocytes. Primary human hepatocytes
were exposed to 20 µM rifampicin for 48 h. (A) mRNA expression of CYP2D6 and CYP3A4 before and after treatment with rifampicin, (B) formation of
1′-OH-midazolam before and after treatment with rifampicin, (C) formation of α-OH-metoprolol before and after treatment with rifampicin, (D) formation of
1′-OH-midazolam, α-OH-metoprolol, O-demethyl-metoprolol, and metoprolol phenylacetate before and after treatment with rifampicin. Experiments for (A–C) were
carried out with lot #Hu8119 and experiments for (D) with lot #Hu8124. Data are presented as mean ± SD. MDZ: midazolam, MTP: metoprolol.
completely be inhibited by 1 µM ketoconazole, at this
concentration a specific CYP3A4 inhibitor (Berger et al., 2016).
Crucially, metoprolol was also α-hydroxylated by CYP3A4
supersomes, but at a much slower rate compared to midazolam.
As shown in Figure 5B, α-hydroxylation of metoprolol could
be inhibited by 1 µM ketoconazole, but not by quinidine, which is
a specific CYP2D6 inhibitor (Hutzler et al., 2003; Ai et al., 2009).
This proved directly that α-hydroxylation of metoprolol could
not only be catalyzed by CYP2D6 but to a small extent also by
CYP3A4.
DISCUSSION
Starting from our in vivo observation that treatment with
rifampicin was associated with an increase in the clearance
of metoprolol, we investigated the metabolic pathways of
metoprolol in different metabolic systems in vitro. In HepaRG
cells and primary human hepatocytes, we could show that
not only CYP2D6 contributes to metoprolol metabolism, but
also other CYP isoforms which are inducible by rifampicin.
Subsequently, we could demonstrate in human liver microsomes
that CYP2D6 is the dominant CYP for metoprolol metabolism,
but that CYP3A4, 2B6, and 2C9 are also involved in the three
major pathways of metoprolol degradation. Finally, we could
confirm these findings directly using CYP3A4 overexpressing
supersomes, which had no CYP2D6 activity but could perform
metoprolol α-hydroxylation.
The in vivo investigations showed a 25% increase in
metoprolol clearance, but only a small (9%) increase in the
AUC of α-OH-metoprolol after CYP induction with rifampicin.
This is consistent with previous findings, which also showed
a decrease in the AUC of metoprolol after CYP induction
(Haglund et al., 1979; Bennett et al., 1982; Derungs et al., 2016).
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FIGURE 4 | Effect of quinidine on the metabolism of metoprolol by human liver microsomes. The quinidine concentration was 1 µM. (A) formation of
α-OH-metoprolol, (B) formation of O-demethyl-metoprolol, (C) formation of metoprolol phenylacetate, and (D) formation of N-deisopropyl-metoprolol. Data are
analyzed in Table 2. Data are presented as mean ± SD. MTP: metoprolol.
The in vivo results could be reproduced in two hepatocyte
models, HepaRG cells (a hepatoma cell line) and primary human
hepatocytes. The results obtained in these cell systems showed
that both α-hydroxylation and O-demethylation of metoprolol
were induced by pre-treatment with rifampicin, while CYP2D6
mRNA expression was not affected.
The lacking increase in CYP2D6 mRNA expression by
rifampicin observed in the current study agrees with other
studies in primary human hepatocytes (Rae et al., 2001; Gerets
et al., 2012; Berger et al., 2016). In enterocytes of human
subjects treated with 600 mg rifampicin for 10 days, the CYP2D6
protein expression increased by a factor of 1.6 without reaching
statistical significance (Glaeser et al., 2005). Post-transcriptional
mechanisms increasing CYP2D6 activity cannot be excluded
based on the current study, but are an unlikely cause for
our observations. In support of this interpretation, sparteine
metabolic clearance, an in vivo marker of CYP2D6 activity
(McGourty et al., 1985), increased by a factor of 1.3 in subjects
treated with rifampicin without reaching statistical significance
(Eichelbaum et al., 1986). Similarly, in primary human
hepatocytes, the activity of dextromethorphan O-demethylation
increased by a factor of 1.3 by treatment with rifampicin without
reaching statistical significance (Madan et al., 2003). In the same
publication, phenobarbital had an almost identical effect on
dextromethorphan O-demethylation as rifampicin (Madan et al.,
2003). Similarly, hypericum extract did not significantly affect the
metabolic ratio of dextrorphan/dextromethorphan, indicating
that CYP2D6 is not induced by this treatment (Wenk et al., 2004).
The data of the current and the previous studies mentioned
above show that CYP2D6 activity is not increased by the classical
inducers of the CYP2B, 2C, and 3A families. The observed
increase in the metoprolol metabolic pathways after treatment
with rifampicin suggested therefore the contribution of CYPs
other than CYP2D6 to metoprolol metabolism. In order to
challenge this hypothesis further, we investigated the metabolism
of metoprolol in human liver microsomes and in CYP3A4
overexpressing supersomes. The data obtained in microsomes
confirmed the contribution of CYP3A4, 2B6, and 2C9 (but
not 2C19) to all 3 major metabolic pathways of metoprolol.
Finally, using CYP3A4 overexpressing supersomes, we could
demonstrate directly that metoprolol can be α-hydroxylated by
CYP3A4.
In human liver microsomes, inhibition of CYP2D6 activity
with quinidine revealed residual activities amassing to 4%
for α-hydroxylation, 8% for N-dealkylation, and 19% for
O-demethylation of metoprolol. Considering these values, it
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TABLE 2 | Metoprolol metabolism by human liver microsomes in the absence (w/o) and presence of inhibitors.
Metabolite formed w/o inhibitor
fmol/min/pmol
CYP
with inhibitor
fmol/min/pmol
CYP
% residual activity (quinidine) or % inhibition
(ketoconazole, ticlopidine, sulfaphenazole,
(+)-N-3-benzylnirvanol)
Quinidine 1 µM (CYP2D6)
O-demethyl-MTP 17.5 ± 0.3 3.32 ± 0.40 19.0 ± 2.1(2.6)
α-OH-MTP 4.11 ± 0.06 0.16 ± 0.06 4.0 ± 0.6(0.70)
MTP-phenylacetate 0.91 ± 0.0.05 0 0
N-dealkyl-MTP 2.91 ± 0.06 0.22 ± 0.05 7.6 ± 1.7(2.1)
Ketoconazole 1 µM (CYP3A4)
O-demethyl-MTP 26.6 ± 0.0.6 22.0 ± 0.0.8 17.5 ± 3.4(4.3)
α-OH-MTP 6.86 ± 0.0.23 5.71 ± 0.29 16.8 ± 2.4(3.0)
N-dealkyl-MTP 4.86 ± 0.29 4.38 ± 0.23 9.9 ± 1.7(2.1)
Ticlopidine 1 µM (CYP2B6)
O-demethyl-MTP 30.3 ± 3.3 24.2 ± 0.34 20.2 ± 8.0(9.9)
α-OH-MTP 7.43 ± 1.14 5.71 ± 0.0.29 23.2 ± 11.1(13.7)
N-dealkyl-MTP 4.97 ± 1.03 3.74 ± 0.23 24.8 ± 12.7(15.8)
Sulfaphenazole 10 µM (CYP2C9)
O-demethyl-MTP 27.7 ± 0.40 20.3 ± 2.4 26.5 ± 10.4(13.2)
α-OH-MTP 6.40 ± 0.23 4.67 ± 0.57 27.0 ± 9.8(12.2)
N-dealkyl-MTP 4.51 ± 0.0.46 3.83 ± 0.74 15.2 ± 14.5(18.0)
(+)-N-3-benzylnirvanol 10 µM (CYP2C19)
O-demethyl-MTP 25.8 ± 0.6 25.0 ± 1.43 3.1 ± 8.4(10.4)
α-OH-MTP 6.23 ± 0.23 6.23 ± 0.0.34 0
N-dealkyl-MTP 4.29 ± 0.17 4.29 ± 0.23 0
Metoprolol metabolites were determined by LC/MS as described in the Section “Materials and Methods.” Activity is given as pmol/min/pmol CYP. Data are given as
mean ± SD and 95%CI in parentheses for residual activity. CYP: cytochrome P450 enzyme, MTP: metoprolol.
FIGURE 5 | α-Hydroxylation of metoprolol and 1′-hydroxylation of midazolam by CYP3A4 overexpressing supersomes. (A) α-Hydroxylation of metoprolol and
1′-hydroxylation of midazolam. 1′-hydroxylation of midazolam was also determined in the presence of 0.5 µM ketoconazole (CYP3A4 inhibitor). (B) α-hydroxylation
of metoprolol in the absence and in the presence of 1 µM quinidine (CYP2D6 inhibitor) or 0.5 µM ketoconazole (CYP3A4 inhibitor). Data are presented as
mean ± SD. MDZ: midazolam, MTP: metoprolol.
has to be taken into account, that the microsomes used in
the current study were obtained from donors without CYP
induction. Based on the data of the current and previous studies
(Haglund et al., 1979; Bennett et al., 1982; Derungs et al.,
2016), it can be assumed that the contribution of CYP3A4,
CYP2C9, and CYP2B6 becomes larger after CYP induction.
In primary human hepatocytes treated with rifampicin, the
production of the metoprolol phenylacetate metabolite (the
end product of the O-demethylation pathway) and of α-OH-
metoprolol increased by 57 and 75%, respectively (Figure 3D),
suggesting that the contribution of CYPs other than CYP2D6 for
metoprolol metabolism can be substantial after CYP induction.
The in vivo study revealed a 25% decrease in the metoprolol AUC,
which is less than expected from the in vitro experiments. This
difference may be due to a more efficient CYP induction under
in vitro conditions, depending on the availability of rifampicin.
In comparison, the increase in the AUC of α-OH-metoprolol in
the in vivo study was only 9%, which can be explained by the only
small contribution of CYPs other than CYP2D6 to this metabolic
step (Figure 4A).
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The question now arises whether metoprolol can be
recommended as a substrate for CYP2D6 phenotyping, taking
into account the contribution of CYPs other than CYP2D6 to
metoprolol metabolism. The problem could be that CYP2D6
poor metabolizers might not be recognized due to the
contribution of CYPs other than CYP2D6, which are not
affected by this polymorphism. In the study of McGourty
et al. (1985), there was a clear separation in renal excretion
of α-OH-metoprolol into debrisoquine EM and PM. Also in
the studies of Tamminga et al. (2001) and of Derungs et al.
(2016), CYP2D6 efficient and poor metabolizers could clearly
be distinguished using α-OH-metoprolol plasma concentrations
or the metoprolol/α-OH-metoprolol ratio. A further potential
problem could be the distinction between CYP2D6 efficient and
poor metabolizers in patients with CYP induction. However, also
in this situation, it was possible to correctly classify patients
using their respective α-OH-metoprolol plasma concentrations
or the metoprolol/α-OH-metoprolol ratio (Derungs et al.,
2016). The findings of the current and of our previous study
(Derungs et al., 2016) suggest that the plasma α-OH-metoprolol
concentration is a better marker of CYP2D6 activity than
the ratio of the metoprolol/α-OH-metoprolol concentrations,
since the contribution of CYPs different from CYP2D6 is
smaller for metoprolol α-hydroxylation than for metoprolol
O-demethylation or N-dealkylation. However, as shown in
the study of Derungs et al. (2016), a correct classification
of CYP2D6 poor metabolizers using the metoprolol/α-OH-
metoprolol ratio was possible under basal conditions and also
after CYP-induction.
CONCLUSION
CYP3A4, 2B6, and 2C9 contribute to metoprolol metabolism,
including α-hydroxylation. This contribution explains a more
pronounced decrease in the metoprolol and a more pronounced
increase in the α-OH-metoprolol plasma concentration after CYP
induction by rifampicin compared to basal conditions. However,
the contribution of CYPs other than CYP2D6 is low and does
not impair the usability of the metoprolol/α-OH-metoprolol
metabolic ratio for CYP2D6 phenotyping, even in patients with
CYP induction by rifampicin.
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